Wall Street Zen Upgrades Arcturus Therapeutics (NASDAQ:ARCT) to Hold

Wall Street Zen upgraded shares of Arcturus Therapeutics (NASDAQ:ARCT - Free Report) from a sell rating to a hold rating in a report published on Thursday.

A number of other research firms have also issued reports on ARCT. HC Wainwright reissued a "buy" rating and issued a $60.00 target price on shares of Arcturus Therapeutics in a report on Thursday, April 10th. Citigroup reiterated a "buy" rating on shares of Arcturus Therapeutics in a research report on Tuesday, May 13th. Canaccord Genuity Group cut their price objective on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. BTIG Research set a $48.00 target price on shares of Arcturus Therapeutics and gave the company a "buy" rating in a report on Monday, March 10th. Finally, Wells Fargo & Company lowered their target price on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Arcturus Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $57.80.

Arcturus Therapeutics Stock Performance

Arcturus Therapeutics stock traded up $0.12 during midday trading on Thursday, hitting $12.32. 127,355 shares of the company's stock were exchanged, compared to its average volume of 450,164. The stock has a market cap of $334.16 million, a price-to-earnings ratio of -5.56 and a beta of 2.36. Arcturus Therapeutics has a 12-month low of $8.04 and a 12-month high of $45.00. The firm's 50 day simple moving average is $11.35 and its 200 day simple moving average is $14.92.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.58) by $1.06. The firm had revenue of $29.38 million for the quarter, compared to analyst estimates of $25.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. On average, equities research analysts forecast that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Byrne Asset Management LLC boosted its stake in shares of Arcturus Therapeutics by 89.8% during the 1st quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 1,365 shares in the last quarter. US Bancorp DE grew its holdings in Arcturus Therapeutics by 218.9% in the first quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 2,329 shares during the last quarter. Virtus ETF Advisers LLC increased its position in shares of Arcturus Therapeutics by 38.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock valued at $69,000 after buying an additional 1,132 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Arcturus Therapeutics during the 4th quarter worth $71,000. Finally, GAMMA Investing LLC grew its stake in Arcturus Therapeutics by 3,482.9% in the 1st quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company's stock valued at $550,000 after acquiring an additional 5,085 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.